Elsevier

Schizophrenia Research

Volume 197, July 2018, Pages 562-563
Schizophrenia Research

Letter to the Editor
Effects of varenicline on cognitive function in non-smokers with schizophrenia

https://doi.org/10.1016/j.schres.2017.03.023Get rights and content

Section snippets

Declaration of funding source

  • Investigator-Initiated Pfizer, Inc. Grant (WI171136)

  • Canadian Institutes of Health Research Operating Grant (MOP#115145)

Declaration of conflicts

Dr. George reports that he has funding support from the Canadian Institutes of Health Research (CIHR) and Pfizer, and is a consultant to Novartis. Ms. Kozak, Dr. Dermody, Dr. Tyndale, Dr. Zack, and Dr. Barr report no conflicts of interest. The authors alone are responsible for the content and writing of this paper.

Acknowledgements

This study was support by an Institute of Medical Sciences Graduate Fellowship from the University of Toronto (to Ms. Kozak), an investigator-initiated grant from Pfizer, Inc. (WI171136) and CIHR Operating Grant MOP#115145 (to Dr. George).

References (12)

  • T.P. George et al.

    Effects of smoking abstinence on visuospatial working memory function in schizophrenia

    Neuropsychopharmacology

    (2002)
  • V.C. Wing et al.

    Varenicline modulates spatial working memory deficits in smokers with schizophrenia

    Schizophr. Res.

    (2013)
  • H.M. Faessel et al.

    A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation

    Clin. Pharmacokinet.

    (2010)
  • T. Hershey et al.

    Short-term and long-term memory in early temporal lobe dysfunction

    Neuropsychology

    (1998)
  • L.E. Hong et al.

    Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder

    Arch. Gen. Psychiatry

    (2011)
  • G.N. Pachas et al.

    Varenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week, open-label trial

    J. Dual Diagn.

    (2012)
There are more references available in the full text version of this article.

Cited by (4)

  • Varenicline improves cognitive impairment in a mouse model of mPFC ischemia: The possible roles of inflammation, apoptosis, and synaptic factors

    2022, Brain Research Bulletin
    Citation Excerpt :

    Furthermore, it has been shown that varenicline is able to reduce inflammation, increase neural regeneration, and improve motor function following the experimental induction of stroke (Chen et al., 2017). In this regard, a number of human and animal studies have proved the procognitive effects of varenicline under different pathological conditions (Huang et al., 2018; Kozak et al., 2018; Lange-Asschenfeldt et al., 2016; Roberts and McKee, 2018; Thompson et al., 2020). The present study was designed to explore the dose-dependent effects of varenicline on cognitive impairments, inflammation, apoptosis, and synaptic indices in mice after mPFC ischemia.

View full text